Novocure Ltd logo

Novocure Ltd(NVCR)

upturn advisory logo
EXPLORE ADVISORIES AND THEIR HISTORY
QUALITY SIGNAL
1-STAR RATING
PASS
LAST CLOSE
$11.83
11/13/2026
(24-hour delay)

Advisory History & Simulated Performance *

*as per simulation (see disclosures)
  • ALL
  • 1Y
  • 1M
  • 1W
  • BUY Advisory
  • SELL Advisory (Profit)
  • SELL Advisory (Loss)
  • Profit
  • Loss
  • PASS (Skip)
Upturn Stock price based on last close iconStock price based on last close
Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Advisory Performance History (Simulated)Advisory Performance History info

Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Upturn Advisory & Investor View for NVCR

11/13/2026: NVCR (1-star) is currently NOT-A-BUY. Pass it for now.

Novocure is a commercial-stage oncology company known for its unique Tumor Treating Fields therapy, a device-based treatment for solid tumors. The company's primary strength lies in its patented, non-invasive technology which provides an alternative to traditional chemotherapies. Its long-term investment story centers on the successful expansion of this platform into large cancer markets like lung and pancreatic cancer. However, the company faces significant execution and competitive risks, including potential failure in clinical trials and competition from well-capitalized pharmaceutical giants. Novocure may best suit growth-oriented investors with a high risk tolerance who are looking for exposure to novel oncology innovation.

How to Read the Upturn Advisory

The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.

Company fundamentals, valuation, risks, and news provide supporting context about the business.

Investor Fit

Investor styleFitWhy
Growth investorStrong fitThe company represents a speculative growth opportunity tied to the potential expansion of its novel therapy platform.
Momentum investorMixed fitThis is a conditional fit dependent on positive clinical trial outcomes or regulatory catalysts.
Value investorWeak fitThe company's lack of consistent profitability and high R&D spending makes it ill-suited for traditional value metrics.
Dividend investorWeak fitNovocure does not pay dividends and prioritizes capital reinvestment.
Low-risk investorWeak fitHigh clinical and regulatory uncertainty makes this unsuitable for low-risk portfolios.

Risk Profile

Risk factorLevelWhy it matters
Price volatilityHighStock performance is highly sensitive to binary clinical trial events and regulatory decisions.
Valuation riskMedium / highHigh premiums are often built into the stock based on future success expectations.
Competition risk (Pharmaceutical Oncology)HighThe company competes against massive, well-funded pharmaceutical firms offering standard-of-care treatments.
Business qualityMediumThe technology is unique, but the company is still establishing a broader product footprint.
Dividend incomeLow / noneInvestors should not expect income from this equity.
Execution riskMedium / highSuccessful commercialization of new indications is essential for long-term survival.

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 1.38B USD
Price to earnings Ratio -
1Y Target Price 26.14
Price to earnings Ratio -
1Y Target Price 26.14
Volume (30-day avg) 1.9M shares
Beta 1.08
52 Weeks Range 9.82 - 21.45
Updated Date 11/14/2026
52 Weeks Range 9.82 - 21.45
Updated Date 11/14/2026
Dividends yield (FY) -
Basic EPS (TTM) -1.06

Sector & Industry Intelligence

Sector

Healthcare

Bullish
Sentiment
Strong Bullish
Momentum
Momentum Steady
BUY participation
62.6%
Active BUY / eligible
72 / 115
30-Day BUY Count Change
+35
Market state
Strong Bullish

The number of qualifying BUY stocks has remained relatively stable.

Industry

Medical Devices

BUY participation
62.5%
Active BUY / eligible
5 / 8
30-Day BUY Count Change
+3

Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.

Price Behavior

Rolling Over
PRICE PATH

Rolling Over

The price momentum is slowing down and beginning to turn downward.

Extreme Price Shocks
PRICE STABILITY

Extreme Price Shocks

The stock has experienced exceptionally large and disruptive price movements during the period.

Analysis of Past Performance

Type Stock
Historic Profit -29.39%
Avg. Invested days 20
Today’s Advisory PASS
Upturn Advisory Rating upturn star rating icon
Upturn Advisory Performance Upturn Advisory Performance icon 2.0
Stock Returns Performance Upturn Returns Performance icon 1.0
Upturn Profits based on simulation icon Profits based on simulation
Upturn last close icon Last Close 11/13/2026

Upturn Scorecard

Upturn Star Rating

★★★★★
NVCR receives a 3-star rating, supported by solid company fundamentals, and solid analyst coverage. The rating is constrained by weak unit economics, and weak price momentum.

Company Fundamentals

★★★★★
NVCR has solid overall fundamentals (4 stars), with moderate financial health, moderate growth momentum, and strong ownership. In FY2025 versus FY2024, solid earnings growth (+19.2%) is partially offset by weak cash generation (FCF margin -11.5%), moderate revenue growth (+8.3%), weak profitability (net margin -20.8%).

Financial Health Rating

★★★★★
NVCR's financial health is supported by solid liquidity, including working-capital and asset support (WC/assets 52.7%). Cash strength is soft (2 stars), which helps explain the 3-star overall score.

Growth Momentum Score

★★★★★
Earnings growth is NVCR's strongest growth driver at +19.2% FY2025 versus FY2024 (solid, 4 stars). By comparison, while free-cash-flow growth (-9.3%, negative) holds the profile back, so recent growth is not broad-based across the business.

Ownership

★★★★★
Institutional ownership is 89.6% and approximately 83.3% of outstanding shares are publicly tradable, supporting liquidity and institutional participation. Insider ownership of 10.00% supports management-shareholder alignment.

Top 5 Institutional Investors

FMR Inc 14.86%
BlackRock Inc 11.47%
Soleus Capital Management, L.P. 8.48%
Vanguard Portfolio Management, LLC 5.37%
Vanguard Capital Management, LLC 4.19%

Unit Economics (Per $1K Revenue)

★★★★★
NVCR generates approximately $745 of gross profit, $-235 of operating income, and $-115 of free cash flow for every $1,000 of revenue. Based on FY2025 results. Operating losses and cash burn explain the 1-star rating, with weak cash conversion and weak capital efficiency.

Economic Dimensions

★★★★★
Effective Tax Rate: 0.02%

Quantitative Style Profile

★★★★★
NVCR has a liquid profile. Weak momentum is the primary drawback.

Style Classification

Quality Focused

Value-OrientedSmall / Mid Cap RiskShort Squeeze RiskHighly Liquid / Institution-Friendly

How Company Makes Money

Business areaWhat it includesRetail investor read
TTFields Device Sales and ServiceRevenue primarily comes from the leasing and sales of Optune and Optune Lua systems, along with associated clinical support services.The company generates revenue by providing proprietary equipment and recurring support for patients undergoing cancer treatment.

Analyzing Revenue: Products, Geography and Growth

Revenue by Geography

Geography revenue - Year on Year

Valuation

Trailing PE -
Forward PE 909.09
Enterprise Value 1.14B
Price to Sales(TTM) 1.91
Enterprise Value 1.14B
Price to Sales(TTM) 1.91
Enterprise Value to Revenue 1.57
Enterprise Value to EBITDA -6.92
Shares Outstanding 116.92M
Shares Floating 97.37M
Shares Outstanding 116.92M
Shares Floating 97.37M
Percent Insiders 10
Percent Institutions 89.62

Financial Metrics

🧭 Investment Snapshot

Total Revenue (Scale)

Information icon Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.

Net Income (Profit)

Information icon Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.

Free Cash Flow (Cash Strength)

Information icon Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.

📈 Growth & Strength

Operating Income (Core Profit)

Information icon Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.

EBITDA (Cash Earnings)

Information icon Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.

Gross Profit (Unit Profitability)

Information icon Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.

🛡️ Financial Safety

Cash (Liquidity Buffer)

Information icon Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.

Total Debt (Leverage Risk)

Information icon Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.

Net Working Capital (Short-Term Health)

Information icon Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.

🧱 Balance Sheet Strength

Stockholder Equity (Net Worth)

Information icon Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.

Total Assets (Asset Base)

Information icon The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.

Income Before Tax (Pre-Tax Earnings)

Information icon Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.

⚙️ Cost & Drag Factors

Cost of Revenue (Production Cost)

Information icon Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.

Total Operating Expenses (Operating Cost)

Information icon Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.

Income Tax Expense (Tax Drag)

Information icon Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Form CRS provides a relationship summary of our automated advisory services, flat subscription fees, and conflicts of interest. Form ADV Part 2A brochure contains complete details on services, billing, and disclosures. If any summary differs from our current regulatory filings, the filed Form ADV controls.